OncoGenex prices $50 million public offering

Friday, March 16, 2012 04:32 PM

OncoGenex Pharmaceuticals, a biopharmaceutical company dedicated to new cancer therapies, has priced an underwritten public offering of 4,165,000 shares of its common stock at a purchase price of $12.00 per share. 

Net proceeds from the offering will approximately amount to $46.8 million, after estimated underwriting discounts and commissions and estimated expenses. OncoGenex granted the underwriters a 30-day option to purchase up to an additional 624,750 shares of common stock to cover overallotments, if any. 

The offering is expected to close on or around March 21, 2012, subject to customary closing conditions.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs